Impact of combination therapy with aminoglycosides on the outcome of ICU-acquired bacteraemias

  • P.-Y. Delannoy
  • N. Boussekey
  • P. Devos
  • S. Alfandari
  • C. Turbelin
  • A. Chiche
  • A. Meybeck
  • H. Georges
  • O. Leroy


Pharmacodynamic studies report on the rapid bactericidal activity of aminoglycosides, conferring them as being of theoretical interest for bacteraemia treatment. We assessed this issue in a retrospective study of patients with intensive care unit (ICU)-acquired bacteraemias. To determine the impact of aminoglycosides in antimicrobial combination on the outcome of patients with bacteraemia, we performed a monovariate analysis and a logistic regression analysis comparing patients treated with or without aminoglycosides. Forty-eight bacteraemias in 48 patients were included. Eighteen patients received aminoglycosides. Baseline characteristics as well as adaptation and adequation of antibiotherapy did not differ in patients who did or did not receive aminoglycosides. Patients who received aminoglycosides had longer time alive away from the ICU (11.3 ± 8.9 (10 [0–20]) vs. 3.2 ± 6.6 (0 [0–2] days; p = 0.002) and free from mechanical ventilation (12.5 ± 9.3 (14 [0–21] vs. 5.5 ± 9.2 (0 [0–10] days; p = 0.02) on day 28. The ICU mortality was 16% in the aminoglycoside group versus 46% (p = 0.03). In the multivariate analysis, patients treated with aminoglycosides were 6 times less likely to die than those treated without aminoglycosides (confidence interval [CI] = [1.3–28.9]; p = 0.02). Our study supports the hypothesis that combination short-term antibiotherapy with an aminoglycoside for ICU-acquired bacteraemias could increase survival.


Intensive Care Unit Colistin Intensive Care Unit Mortality Logistic Regression Multivariate Analysis Model Increase Intensive Care Unit Mortality 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L (2004) Beta lactam monotherapy versus beta lactam–aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 328:668PubMedCrossRefGoogle Scholar
  2. 2.
    Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME (2005) Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 41:149–158PubMedCrossRefGoogle Scholar
  3. 3.
    Safdar N, Handelsman J, Maki DG (2004) Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 4:519–527PubMedCrossRefGoogle Scholar
  4. 4.
    Furno P, Bucaneve G, Del Favero A (2002) Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2:231–242PubMedCrossRefGoogle Scholar
  5. 5.
    Vallés J, Rello J, Ochagavía A, Garnacho J, Alcalá MA (2003) Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 123:1615–1624PubMedCrossRefGoogle Scholar
  6. 6.
    Vallés J, León C, Alvarez-Lerma F (1997) Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis. Spanish Collaborative Group for Infections in Intensive Care Units of Sociedad Espanola de Medicina Intensiva y Unidades Coronarias (SEMIUC). Clin Infect Dis 24:387–395PubMedCrossRefGoogle Scholar
  7. 7.
    Corona A, Bertolini G, Lipman J, Wilson AP, Singer M (2010) Antibiotic use and impact on outcome from bacteraemic critical illness: the BActeraemia Study in Intensive Care (BASIC). J Antimicrob Chemother 65:1276–1285PubMedCrossRefGoogle Scholar
  8. 8.
    Alfandari S, Boussekey N (2005) Beta-lactams with or without aminoglycosides. Clin Infect Dis 41:1542–1543PubMedCrossRefGoogle Scholar
  9. 9.
    Marik PE, Lipman J, Kobilski S, Scribante J (1991) A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 28:753–764PubMedCrossRefGoogle Scholar
  10. 10.
    Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH (1997) Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 39:677–686PubMedCrossRefGoogle Scholar
  11. 11.
    Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL (1999) Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 43:1549–1555PubMedGoogle Scholar
  12. 12.
    Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963PubMedCrossRefGoogle Scholar
  13. 13.
    Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710PubMedCrossRefGoogle Scholar
  14. 14.
    Bell DM (2001) Promoting appropriate antimicrobial drug use: perspective from the Centers for Disease Control and Prevention. Clin Infect Dis 33(Suppl 3):S245–S250PubMedCrossRefGoogle Scholar
  15. 15.
    Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative workgroup (2004) Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8:R204–R212PubMedCrossRefGoogle Scholar
  16. 16.
    Allan JD, Moellering RC Jr (1985) Management of infections caused by Gram-negative bacilli: the role of antimicrobial combinations. Rev Infect Dis 7(Suppl 4):S559–S571PubMedCrossRefGoogle Scholar
  17. 17.
    Garnacho-Montero J, Ortiz-Leyba C, Herrera-Melero I, Aldabó-Pallás T, Cayuela-Dominguez A, Marquez-Vacaro JA, Carbajal-Guerrero J, Garcia-Garmendia JL (2008) Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study. J Antimicrob Chemother 61:436–441PubMedCrossRefGoogle Scholar
  18. 18.
    Kuti EL, Patel AA, Coleman CI (2008) Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care 23:91–100PubMedCrossRefGoogle Scholar
  19. 19.
    Fraser A, Paul M, Almanasreh N, Tacconelli E, Frank U, Cauda R, Borok S, Cohen M, Andreassen S, Nielsen AD, Leibovici L; TREAT Study Group (2006) Benefit of empirical appropriate antibiotic treatment: thirty-day mortality and duration of hospital stay. Am J Med 119:970–976PubMedCrossRefGoogle Scholar
  20. 20.
    Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C (2003) Impact of adequate antibiotic empirical therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 31:2742–2751PubMedCrossRefGoogle Scholar
  21. 21.
    Rougier F, Claude D, Maurin M, Sedoglavic A, Ducher M, Corvaisier S, Jelliffe R, Maire P (2003) Aminoglycoside nephrotoxicity: modeling, simulation, and control. Antimicrob Agents Chemother 47:1010–1016PubMedCrossRefGoogle Scholar
  22. 22.
    Beauchamp D, Labrecque G (2001) Aminoglycoside nephrotoxicity: do time and frequency of administration matter? Curr Opin Crit Care 7:401–408PubMedCrossRefGoogle Scholar
  23. 23.
    Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L (2006) Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 25:CD003344Google Scholar
  24. 24.
    Leibovici L, Vidal L, Paul M (2009) Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob Chemother 63:246–251PubMedCrossRefGoogle Scholar
  25. 25.
    Marcus R, Paul M, Elphick H, Leibovici L (2011) Clinical implications of β-lactam-aminoglycoside synergism: systematic review of randomised trials. Int J Antimicrob Agents 37:491–503PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • P.-Y. Delannoy
    • 1
  • N. Boussekey
    • 1
  • P. Devos
    • 2
  • S. Alfandari
    • 1
  • C. Turbelin
    • 1
  • A. Chiche
    • 1
  • A. Meybeck
    • 1
  • H. Georges
    • 1
  • O. Leroy
    • 1
  1. 1.Intensive Care and Infectious Disease Unit, Tourcoing HospitalUniversity of LilleTourcoing CedexFrance
  2. 2.Department of BiostatisticsUniversity HospitalLilleFrance

Personalised recommendations